lifespin is aiming to revolutionize healthcare by integrating advanced metabolomic analysis with AI-driven algorithms to deliver hypothesis-free, precise, scalable, and cost-effective health assessment solutions. Addressing the limitations of reactive healthcare models, lifespin’s proprietary cloud-based SaaS platform leverages Nuclear Magnetic Resonance (NMR) spectroscopy to create digital metabolomic twins from blood samples, which are analyzed to enable proactive health management and precision medicine. The company’s flagship product, the General Health Assessment “MetaboPro”, with up to 250 quantitative biomarkers, already provides comprehensive insights into diabetes & metabolic risks, liver and kidney health, inflammation, and cardiovascular risks. Further modules, including gut health, energy metabolism, lung, muscle health, and thyroid function will be introduced subsequently throughout the upcoming years.

Priced about 10x lower than legacy solutions, their General Health Assessment makes prevention accessible. With proprietary software and global partnerships, lifespin ensures scalability and accuracy. In the Middle East, this technology aims to reduce chronic disease burdens, fostering a proactive wellness culture that transforms healthcare from reactive to preventive, enhancing quality of life. The exclusive conversation with Dr. Ali Tinazli includes new information, read it to understand more.

MedEdge MEA: What did you see in lifespin that made you sure it could change the way healthcare does diagnostics?

Dr. Ali Tinazli: Lifespin opens a new window into human health by mapping the metabolome – the body’s real-time chemistry – and detecting early pattern changes long before legacy IVD tests or a conventional check-up would. Our platform delivers this insight faster, more affordably, and without pre-set hypotheses. The first product, the General Health Assessment, is a prevention tool – not a diagnostic. Like a car dashboard, it alerts you early so you can see your healthcare provider before problems escalate.

By digitizing blood chemistry, the human metabolome, the next frontier after genomics and proteomics, lifespin is catalyzing the Middle East’s digital transformation in healthcare, shifting from reactive treatment to preventive, personalized care, and building the digital twin technology that can anchor the region’s future of medicine.

We’ve built one of the world’s largest and most standardized metabolomic biobanks, over 270,000 human profiles, protected by consent, compliance, and proprietary know-how. It’s like having a high-resolution health map no one else has, and that’s a cornerstone of why we can lead this space.

ME: Lifespin has built a database of over 250,000 human metabolomic profiles and can identify more than 700 diseases in minutes. What has been the most surprising finding?

AT: Today, our curated, fully digitized biobank holds over 270,000 human samples, tagged with ICD-10 codes across 700+ disease areas, from metabolic diseases, oncology, neurology to mental health. This foundational dataset gives us deep insight into disease phenotypes, driving our R&D pipeline.

The real breakthrough is not just measuring hundreds of molecules, it is interpreting them together, spotting patterns that reveal early disease risks invisible to routine blood tests. Importantly, our current General Health Assessment does not diagnose; it builds the prevention habit. Once this is established, we will roll out disease-specific software modules for diagnosis, risk stratification, and progression monitoring, always in compliance with regulatory frameworks.

ME: You’ve compared your test’s cost to a margherita pizza. How do you keep it affordable without losing quality or innovation?

AT: Digitizing a human blood sample with a 5-minutes NMR measurement costs about the same as a pizza margherita. Software fees are added, but even so, a General Health Assessment can retail around USD 100 while leaving sustainable margins for all stakeholders. As we expand into disease-specific verticals, pricing will vary, but always remain 5–10 times less expensive than traditional methods. This model keeps the test accessible while fueling ongoing innovation.

ME: With lifespin already present in the Middle East, what impact do you expect your technology to have on healthcare outcomes there?

AT: In the Middle East, diabetes and stroke are a major health burden. Our preventive General Health Assessment will help by increasing awareness and giving individuals actionable health information early. Making such insights broadly available is the first critical step toward a population that is more health-conscious, takes preventive measures, and ultimately reduces the incidence and cost of severe disease, and most importantly maintains or increase the quality of people’s life.

ME: What kinds of diseases can your platform address now, and what’s coming next?

AT: Our platform can already model early risks for diseases from diabetes and insulin resistance to cardiovascular risk, liver health, and inflammation. We’re now expanding into kidney, lung, thyroid, muscle metabolism, rheumatoid arthritits, and even neurological conditions. And of course: all these areas have also impact on aging, longevity, and healthspan. This broad coverage is possible because we analyze the metabolome as a whole, not single markers, making it possible to detect patterns traditional tests miss.

ME: What stops others from simply copying your approach?

AT: The key differentiator is our proprietary software platform in combination with our vast, highly curated, proprietary, and fully digitized biobank. It does interpret clinical-grade, quantitative, and highly reproducible metabolomic data and makes NMR-based testing twice as fast as standard protocols, unlocking real-world scalability. Without our software and extensive reference datasets, the raw NMR spectra remain clinically illegible, and the operational efficiency to serve large health systems just is not there.

Our automated platform can process hundreds of samples per day and instrument, with turnaround in hours – making preventive testing viable at national scale. We also work with leading hospitals and research groups worldwide to ensure our models are validated across diverse populations.

ME: Where do you see lifespin’s role in the long-term future of healthcare?

AT: We see a future where your health is monitored like your car – continuously, proactively, and with the ability to fix small issues before they become big ones. Ideally, we help reducing the cost-burden of the skyrocketing rates of non-communicable diseases (NCDs) by establishing with our regional partners preventive measure. Our mission is to make preventive, personalized health management as routine and expected as regular maintenance, transforming healthcare from reactive crisis management into proactive lifelong wellness.